GLP-1 & Incretin Science

What Is Cagrilintide? The Amylin Half of CagriSema

UKPWritten and published by UK Peptides2 min readUpdated 4 cited sources

The short answer

Cagrilintide is a long-acting analogue of amylin, the satiety hormone co-secreted with insulin. Engineered for once-weekly administration, it is the amylin component of CagriSema. Native human amylin cannot be used as a drug because it aggregates into amyloid fibrils.

Key facts

Class
Long-acting amylin receptor agonist
Developer
Novo Nordisk
Molecular weight
~4,409 Da
Molecular formula
C194H312N54O59S2
PubChem CID
171397054
Administration
Once weekly, subcutaneous
Combined with
Semaglutide, as CagriSema
Predecessor
Pramlintide (meal-time dosing)

The problem native amylin presents

Human amylin is a 37-residue hormone that aggregates readily into amyloid fibrils. That is not merely a formulation nuisance; it is the same process that deposits islet amyloid in type 2 diabetes. A drug that self-assembles into insoluble fibrils in the vial or at the injection site is not viable, which is why amylin analogues had to solve aggregation before they could solve anything else.

How the problem was first solved

Pramlintide, the first clinical amylin analogue, borrowed proline substitutions from rat amylin, which does not aggregate. Those substitutions disrupted the sequence's propensity to form the ordered structure amyloid requires. Pramlintide worked but had a short half-life and needed dosing with meals, which limited its practical use.

Research material referenced

Retatrutide 10mg, third-party HPLC tested

Buy Retatrutide · £59.99

What cagrilintide changes

Cagrilintide is engineered for once-weekly administration, which brings amylin pharmacology into the same dosing rhythm as the modern GLP-1 analogues. That matters for combination: pairing a weekly GLP-1 agonist with a meal-time amylin analogue would be impractical, whereas two weekly components can be delivered as a single fixed-dose product.

Why pair it with semaglutide at all

Amylin and GLP-1 reduce food intake through largely separate routes, amylin principally via the area postrema and GLP-1 via hypothalamic and vagal pathways. Because the pathways do not fully overlap, their effects add rather than saturate. REDEFINE 1 tested exactly this, comparing the combination against each component alone, and the combination outperformed both.

The evidence behind the combination

REDEFINE 1, in adults with obesity and without diabetes, reported 22.7% mean reduction at 68 weeks among participants who adhered and 20.4% across all randomised, against 2.3% and 3.0% on placebo respectively. REDEFINE 2, in adults with type 2 diabetes, reported 15.7% at 68 weeks against 3.1% on placebo. That is a smaller figure, which is the expected pattern in diabetic populations across the entire class.

Status

Cagrilintide is investigational as a single agent. As part of CagriSema it has been filed with the FDA. Novo Nordisk expected a decision in the fourth quarter of 2026 (report of 4 November 2026); none had been announced by 21 November 2026. It holds no MHRA authorisation.

Frequently asked questions

Is cagrilintide a GLP-1 drug?

No. It is an amylin analogue. Amylin is a separate hormone with its own receptor complex and its own satiety pathway.

Why can native amylin not be used?

It aggregates into amyloid fibrils. Clinical analogues substitute residues at the aggregation-prone positions to prevent it.

How does it differ from pramlintide?

Pramlintide is short-acting and requires dosing with meals. Cagrilintide is engineered for once-weekly administration, which makes weekly combination products possible.

Continue researching

Related guides and reference material.

Primary sources & clinical trials

Published papers, trial registrations, regulator pages and company announcements. Links open the original.

UKP

Written and published by UK Peptides, the trading name of AURYXRESEARCH LTD (company 17388727, registered in England and Wales).

Questions or a correction? Email hello@ukpeptides.org or call +44 7426 987848.

Corrections log

More GLP-1 & Incretin Science articles

Research use only. The information above is provided for scientific and educational reference. Compounds referenced are not approved for human use and are supplied for in vitro research or reference-material purposes only. No efficacy, safety, or therapeutic claims are made.